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Abstract
Background: Methicillin resistant Staphylococcus aureus (MRSA) is an increasingly common cause
of nosocomial infections, causing severe morbidity and mortality worldwide, and accounting in
some hospitals for more than 50% of all S. aureus diseases. Treatment of infections caused by
resistant bacterial pathogens mainly relies on two therapeutic modalities: development of new
antimicrobials and use of combinations of available antibiotics.
Combinations of antibiotics used in the empiric treatment of infections with suspected methicillin
resistant Staphylococcus aureus etiology were investigated.
Methods: Double (vancomycin or teicoplanin with either levofloxacin or cefotaxime) and triple
(vancomycin or teicoplanin + levofloxacin + one among amikacin, ceftazidime, cefepime, imipenem,
piperacillin/tazobactam) combinations were evaluated by means of checkerboard assay and time kill
curves. Mutational rates of single and combined drugs at antimicrobial concentrations equal to the
resistance breakpoints were also calculated.
Results: Vancomycin or teicoplanin + levofloxacin showed synergy in 16/50 and in 9/50 strains
respectively, while vancomycin or teicoplanin + cefotaxime resulted synergic for 43/50 and 23/50
strains, respectively. Triple combinations, involving teicoplanin, levofloxacin and ceftazidime or
piperacillin/tazobactam gave synergy in 20/25 strains. Teicoplanin + levofloxacin gave synergy in
triple combinations more frequently than vancomycin + levofloxacin.
For single antibiotics, mutational frequencies ranged between 10-5 and <10-9 for levofloxacin,
cefotaxime, amikacin and imipenem, and <10-9 for vancomycin and teicoplanin. When tested in
combinations, mutational frequencies fell below 10-9 for all the combinations.
Conclusion: In vitro evidence of synergy between glycopeptides, fluoroquinolones (levofloxacin)
and β-lactams and of reduction of mutational frequencies by combinations are suggestive for a
potential role in empirical therapy of severe pneumonia with suspected MRSA etiology.
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Prevalence of bacterial pathogens resistant to the available
antibiotics has been increasing over the past several dec-
ades. This feature represents a major challenge for devel-
oping innovative therapeutic modalities, particularly for
treatment of Gram-positive infections. Among these,
methicillin resistant Staphylococcus aureus (MRSA) is an
increasing common cause of nosocomial infections, caus-
ing severe morbidity and mortality worldwide, and
accounting in some hospitals for more than 50% of all S.
aureus diseases [1-4]. Methicillin resistance was firstly
identified in 1961 among nosocomial isolates of S. aureus
and, till the last 10 years, was mainly restricted to the
nosocomial setting [5]. However in the past decade new
strains of MRSA in the community have been increasingly
isolated reaching even 30% in some areas [6,7]. Of partic-
ular concern is that methicillin resistance, particularly in
nosocomial strains, is often associated with resistance to
other antibiotics such as macrolides and fluoroquinolo-
nes, so that glycopeptides and the oxazolidinones consti-
tute the only available therapeutic options, once an MRSA
infection has been diagnosed.
In the last years new antimicrobials specifically targeted
against Gram-positive or MRSA strains have been
launched, but strains with decreased susceptibility to
these antibiotics have been increasingly isolated and,
unfortunately, development of new antimicrobial agents
in the next future seems to be declining [8-10]. On the
other hand, antimicrobial combination therapy should be
useful in improving efficacy, providing broad-spectrum
coverage and preventing the emergence of resistant
mutants [11]. Moreover, combination therapy is argued
when empirical treatment of severe infections is needed,
such as in severe pneumonia. As an etiological diagnosis
with susceptibility results is almost never available to
assist in the selection of the prompt therapy, the initial
approach to treatment is largely empirical and is ordinar-
ily guided by consensus guidelines. Moreover, early
administration of appropriate empirical therapy for severe
pneumonia has been demonstrated to significantly
improve survival [12]. For this reason, antimicrobial ther-
apy should cover both Gram-positive and Gram-negative
bacteria, until obtainment of laboratory results. Guide-
lines from the American Thoracic Society suggest to add
an anti-MRSA agent for treatment of pneumonia when
MRSA is suspected, so that double or triple antimicrobial
combinations are often used [13].
Despite their wide use, antimicrobial activity of antibiot-
ics' combinations, particularly when more than two drugs
are associated, is only rarely assessed in in vitro assays.
This study has been addressed to rate the interaction
between glycopeptides (vancomycin and teicoplanin) and
a β-lactam (cefotaxime) or a fluoroquinolone (levo-
floxacin) and among glycopeptides, a fluoroquinolone
(levofloxacin) and either an aminoglycoside (amikacin)
or a β-lactam (cefepime, ceftazidime, imipenem, pipera-
cillin/tazobactam), which are suggested for empirical
combinations in the hospital setting when a MRSA etiol-
ogy is suspected [13]. Moreover, frequency of spontane-




Fifty MRSA clinical strains were isolated from low respira-
tory tract infections in patients hospitalized at L. Sacco
Teaching Hospital of Milan, Italy. Isolates were identified
using conventional automated methodologies (Vitek 2,
BioMerieux, Marcy L'Etoile, France). Methicillin resistance
was confirmed by oxacillin disk test in accordance with
CLSI (formerly NCCLS) and Nitrocefin test [14,15]. Only
one isolate for patient was considered in order to avoid
duplicates. All isolates were stored in brain-heart infusion
broth containing 10% (w/v) glycerol at -80°C until use.
Antibiotics
Levofloxacin (LVX), cefotaxime (CTX), teicoplanin (TEC)
(Sanofi-Aventis), amikacin (AMK), vancomycin (VA)
(Sigma Aldrich), cefepime (FEP) (Bristol Myers Squibb),
ceftazidime (CAZ) (Glaxo Smith Kline), imipenem (IPM)
(Merck Sharp & Dohme) and piperacillin/tazobactam
(TZP) (Wyeth Lederle) as powder of stated potency, were
used to prepare stock solutions at concentrations of 5120
mg/L as suggested by CLSI [14,15].
Determination of MIC
Determination of MIC was performed by means of micro-
dilution broth method (microwell method) in accordance
to CLSI [14,15]. S. aureus ATCC 29213 was used as quality
control.
Evaluation of synergy
Double combinations comprised a glycopeptide (VA or
TEC) with either LVX or CTX. Triple combinations were
composed by glycopeptide (VA or TEC), fluoroquinolone
(LVX) plus either an aminoglycoside (AMK) or a β-lactam
(FEP, CAZ, IPM, TZP).
Checkerboard
MICs of each antibiotic alone or in combination were
determined by broth microdilution technique in accord-
ance to CLSI standards by using cation adjusted Mueller-
Hinton broth as modified for a broth microdilution
checkerboard procedure [14-16]. For the double combi-
nations a two-dimensional checkerboard with twofold
dilutions of each drug was used for the study. The triple
combinations were tested by a three-dimensional checker-Page 2 of 7
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with twofold dilutions of LVX and either VA or TEC was
set up as described above for the double combinations.
The third component of the combination was added at a
single concentration per plate. Growth control wells con-
taining medium were included in each plate. Each test was
performed in duplicate. For the first clear well in each row
of the microtiter plate containing all antimicrobial agents,
the fractional inhibitory concentration (FIC) was calcu-
lated as follows: FIC of drug A (FICA) = MIC of drug A in
combination/MIC of drug A alone, FIC of drug B (FICB) =
MIC of drug B in combination/MIC of drug B alone, FIC
of drug C (FICC) = MIC of drug C in combination/MIC of
drug C alone [17]. FIC Index (FICi), calculated as the sum
of each FIC, was interpreted as follows: FICi ≤ 0.5 = syn-
ergy, FICi > 4.0 = antagonism and FICi > 0.5–4 = no inter-
action [18].
Double combinations were tested on 50 MRSA strains, tri-
ple combinations on 25 MRSA strains.
Time-kill curves
Time kill curve were performed on five randomly selected
MRSA strains, among those showing the lowest MICs.
Time-kill assays were performed in Mueller Hinton broth
inoculated with each isolate to a final concentrations of
1–5 × 105 cfu/mL.
Antibiotics were tested alone and in double combinations
at concentrations equal to 1 × MIC, 1/2 × MIC, 1/4 × MIC
or in triple combinations at concentrations of 1 × MIC, 1/
2 × MIC, 1/4 × MIC and 1/8 × MIC. After 0, 2, 6, 12 and
24 hours of incubation, aliquots of bacterial culture were
serially diluted and plated on to Mueller Hinton agar for
colony counts.
Synergy was defined as a 2 log10 decrease in colony counts,
when antibacterial activity of combinations was com-
pared with that of the most active single agent. Indiffer-
ence was defined as <2 log10 increase in colony count at 24
h by the combination compared by the most active single
agent. Antagonism was defined as a ≥2 log10 increase in
colony count at 24 h by the combination compared with
that by the most active single agent alone [17].
Mutational frequency
The frequency of spontaneous single-step mutations was
determined on 10 strains of MRSA by spreading 0.1 mL
from a bacterial suspension of about 1010 CFU/mL on
antibiotic free agar plates (after proper dilution) and on
antibiotic containing agar plates (undiluted inoculum)
[19]. CLSI resistance breakpoints were used to define anti-
biotic concentrations in each plate [15]. Colonies grown
after 48 h of incubation at 37°C were counted. Frequency
of mutation was calculated as the number of colonies
grown on antibiotic containing plates per inoculum. Only




Microbial susceptibilities to the tested antibiotics are
shown in Table 1. All the strains were resistant to cefotax-
ime, and most of them were resistant also to levofloxacin,
while they were all susceptible to vancomycin and teico-
planin. Three strains were found resistant to amikacin,
while no appreciable activity against MRSA was observed
for ceftazidime, cefepime, imipenem and piperacillin/
tazobactam.
Table 1: Antimicrobial activity of antibiotics tested in the study on clinical MRSA strains
Number of strains having MIC (µg/ml) equal to:







3 (3) 4 (2)
CTX 34 3 5 2 2 2 2
VA 3 (1) 9 (3) 20 (13) 18 (8)
TEC 2 (1) 3 (1) 23 (12) 12 (5) 6 (3) 4 (3)
AMK 1 2 2 3 10 6 1
CAZ 7 13 2 3
FEP 15 4 2 4
IPM 5 13 3 2 2
TZP 3 14 2 2 2 1 1
*: Data in parenthesis refer to strains used in triple combinations; LVX: levofloxacin; CTX: cefotaxime; VA: vancomycin; TEC: teicoplanin; AMK: 
amikacin; CAZ: ceftazidime; FEP: cefepime; IPM imipenem; TZP: piperacillin/tazobactam.Page 3 of 7
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Checkerboard
As shown in Table 2, all combinations showed synergy or
no interaction, while no antagonism was found in the
checkerboard assays. In particular, among double combi-
nations CTX + TEC gave the highest rate of synergy (43/
50), followed by CTX + VA (23/50), LVX+ VA (16/50) and
LVX + TEC (9/50).
Triple combinations of levofloxacin resulting synergic on
the highest number of strains involved TEC with either
CAZ or TZP (20/25 strains), while combinations with TEC
and either AMK or FEP or IPM yielded synergy in 10/25
strains. Among the combinations of LVX with VA, the
highest rate of synergy was observed in those with CAZ
(15/25), followed by combinations with FEP (10/25) and
with AMK or IMP or TZP which resulted synergic in a
small portion of the tested MRSA strains (5/25).
Time-kill curves
In double combinations, synergy occurred earlier with
combinations involving TEC/VA and CTX. As shown in
table 3, TEC/VA + CTX showed synergy in all the tested
strains after 12 h, while the same result was obtained with
LVX combinations after 24 h.
Triple combinations of TEC with LVX generally showed an
overall high degree of synergy if compared with combina-
tions with VA. Combinations of TEC with LVX and β-
lactams gave synergy against at least 1 out of the 5 strains
tested after 12 h, while at the same time LVX + VA showed
synergy only with IPM and TZP. After 24 h, combinations
with TEC showed synergy for 3/5 strains when the third
antibiotic was a β-lactam and for 4/5 strains when com-
bined with AMK. At the same time, combinations with VA
were synergic for 2/5 strains with CAZ and TZP and for 3/
5 strains when LVX and VA were combined with AMK, FEP
and IPM.
No antagonistic effects were observed with all the tested
combinations, while indifference was found for the all the
other strains.
Mutational frequency
For single antibiotics, mutational frequencies at break-
point antibiotic concentrations ranged between 10-5 and
<10-9 for LVX, CTX, AMK and IMI, and were <10-9 for VA
and TP, while they were not determined for CAZ, CPM
and PTZ since none of the tested strains was susceptible to
these drugs (Tables 4 and 5). When tested in double and
triple combinations, mutational frequencies fell below
10-9 for all the tested antibiotics.
Discussion
Antimicrobial combination therapy may be used to
extend spectrum coverage, prevent the emergence of
resistant mutants and gain synergy between antimicrobi-
als [11]. Combination therapy is often recommended for
empirical treatment of bacterial infections in intensive
care units, where monotherapy is not likely to cover all
potential pathogens, and the emergence of resistance is a
potential threat [20]. In the last years, development of
new antimicrobials targeted to treatment of MRSA infec-
tions, such as linezolid, has led to assess antibacterial
activity of such drugs in combination with several antibac-
terials, particularly β-lactams [21-24]. Also combination
of vancomycin with aminoglycoside or β-lactams has
been widely investigated, generally reporting synergy with
Table 2: Interaction as determined by means of checkerboard assay
Combination Nr of MRSA strains (%) for which combinations gave
Synergy No interaction Antagonism
LVX + VA (n = 50) 16 (32) 34 (68) 0
LVX + TEC (n = 50) 9 (18) 41 (82) 0
CTX + VA (n = 50) 23 (46) 27 (54) 0
CTX + TEC (n = 50) 43 (86) 7 (14) 0
LVX + VA + AMK (n = 25) 5 (20) 20 (80) 0
LVX + TEC + AMK (n = 25) 10 (40) 15 (60) 0
LVX + VA + CAZ (n = 25) 15 (60) 10 (40) 0
LVX + TEC + CAZ (n = 25) 20 (80) 5 (20) 0
LVX + VA + FEP (n = 25) 10 (40) 15 (60) 0
LVX + TEC + FEP (n = 25) 10 (40) 15 (60) 0
LVX + VA + IPM (n = 25) 5 (20) 20 (80) 0
LVX + TEC + IPM (n = 25) 10 (40) 15 (60) 0
LVX + VA + TZP (n = 25) 5 (20) 20 (80) 0
LVX + TEC + TZP (n = 25) 20 (80) 5 (20) 0
LVX: levofloxacin; VA: vancomycin; TEC: teicoplanin; CTX: cefotaxime; AMK: amikacin; CAZ: ceftazidime; FEP: cefepime; IPM: imipenem; TZP: 
piperacillin/tazobactam.Page 4 of 7
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observed with aminoglycosides [25-28]. Activity of com-
binations containing teicoplanin against S. aureus has
been less investigated [27,28]. The present study has com-
pared antimicrobial combinations containing teicoplanin
or vancomycin for their antibacterial activity and ability to
select for mutants able to grow in their presence in noso-
comial MRSA. To our knowledge this is the first study
evaluating the efficacy of triple combinations of a glyco-
peptide, a β-lactam and a fluoroquinolone against MRSA
strains. Triple combinations with vancomycin have been
recently indicated by American Thoracic Society and
Infectious Diseases Society of America for initial empiric
therapy for hospital acquired pneumonia, ventilator asso-
ciated pneumonia and healthcare associated pneumonia
in patients with potential MRSA etiology [13]. These
guidelines suggest the use of vancomycin or, as alterna-
tive, of linezolid, combined with one among antipseu-
domonal cephalosporins or carbapenems or β-lactam/β-
lactamase inhibitor (i.e. piperacillin-tazobactam) and an
antipseudomonal fluoroquinolone or an aminoglycoside.
Teicoplanin is not included, since it has not been
approved in the United States, however, in all countries
where it has been approved, teicoplanin represents an
alternative to vancomycin [13]. In this study, data from
the checkerboard assay indicates that teicoplanin with
cefotaxime showed the highest rate of synergy among the
tested combinations, followed by those with levofloxacin
and ceftazidime or piperacillin/tazobactam. Ability of β-
lactams in triple combinations to yield synergy was quite
different for the various molecules, ranging from 20 to
80%.
Killing curves confirmed superior activity of teicoplanin
plus cefotaxime, while smoothed differences among β-
lactams. Since in in vitro experiments glycopeptides are
slowly bactericidal, it may be hypothesized that their
antistaphylococcal bactericidal activity could be increased
by use of combinations [29]. It is also evident that this
ability was not a class effect since marked differences were
found among β-lactams tested and between the two glyc-
opeptides. Therefore it seems rather difficult to compare
our data with those of other studies in which different β-
lactams have been used.
Methicillin resistance is known to favor development of
multi-drug resistance, including macrolides and fluoro-
quinolones. In fact, for the strains evaluated in this study,
Table 4: Mutational frequencies of levofloxacin, vancomycin, teicoplanin and cefotaxime alone and in double combination
Strain Single antibiotics Double 
combinations*
LVX VA TEC CTX
7095 <10-9 <10-9 <10-9 n.d. <10-9
7096 <10-9 <10-9 <10-9 n.d. <10-9
8957 1.65 × 10-5 <10-9 <10-9 n.d. <10-9
7176 1.81 × 10-6 <10-9 <10-9 n.d. <10-9
7171 <10-9 <10-9 <10-9 n.d. <10-9
2106 <10-9 <10-9 <10-9 n.d. <10-9
6556 2.86 × 10-7 <10-9 <10-9 5.47 × 10-5 <10-9
7169 n.d. <10-9 <10-9 1.22 × 10-5 <10-9
7955 n.d. <10-9 <10-9 n.d. <10-9
8363 n.d. <10-9 <10-9 n.d. <10-9
LVX: levofloxacin; VA: vancomycin; TEC: teicoplanin; CTX: cefotaxime.
n.d.: not determined (strain resistant to the antibiotic)
*Double combinations: LVX + VA; LVX + TP; CTX + VA; CTX + TP
Table 3: Evaluation of synergy: time killing curves on 5 MRSA 
strains
Combination Nr of strains showing 
synergy/indifference at:
2 h 6 h 12 h 24 h
LVX + VA 0/5 0/5 2/3 5
LVX + TEC 0/5 0/5 3/2 5/0
CTX + VA 0/5 1/4 5/0 5/0
CTX + TEC 0/5 0/5 5/0 5/0
LVX + VA + AMK 0/5 0/5 0/5 3/2
LVX + TEC + AMK 0/5 0/5 0/5 4/1
LVX + VA + CAZ 0/5 0/5 0/5 2/3
LVX + TEC + CAZ 0/5 1/4 2/3 3/2
LVX + VA + FEP 0/5 0/5 0/5 3/2
LVX + TEC + FEP 0/5 0/5 1/4 3/2
LVX + VA + IPM 0/5 0/5 1/4 3/2
LVX + TEC + IPM 0/5 1/4 2/3 3/2
LVX + VA + TZP 0/5 0/5 2/3 2/3
LVX + TEC + TZP 0/5 0/5 3/2 3/2
LVX: levofloxacin; VA: vancomycin; TEC: teicoplanin; CTX: 
cefotaxime; AMK: amikacin; CAZ: ceftazidime; FEP: cefepime; IPM: 
imipenem; TZP: piperacillin/tazobactam.Page 5 of 7
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otic in single was not always possible, since they were
already resistant to the molecules tested and therefore
able to grow at antibiotic concentrations equal to the
resistant breakpoint. Data obtained indicate that glyco-
peptides in double or triple combinations were effective
in preventing the emergence of mutants able to grow in
presence of the antibiotics. No mutants were isolated in
vitro after incubation with glycopeptides alone, thus corre-
lating the low frequency of development of glycopeptides
resistance observed in vivo. Different results have been
reported for teicoplanin and vancomycin after serial expo-
sure to these antibiotics by other authors, but the differ-
ences between the methods employed are likely the cause
of this discrepancy [30-33]. However, further studies on
development of resistance possibly induced by the tested
antibiotics in single and in combinations after serial pas-
sages are now in progress.
Conclusion
In summary, double and triple combinations of glycopep-
tides with levofloxacin and/or β-lactams were studied as
far as synergy and frequency of mutations were concerned
in a congruent number of MRSA strains. High rates of syn-
ergy were obtained for some combinations including
teicoplanin, while combinations with both glycopeptides
reduced frequency of mutations to not detectable levels.
Although in vitro studies need to be confirmed by in vivo
findings, the data obtained support the use of antimicro-
bial combinations including glycopeptides and β-lactams
in initial empirical therapy of severe pneumonia, poten-
tially sustained by MRSA and non fermenting gram-nega-
tive bacteria, limiting the development of mutants able to
grow in presence of antibiotics.
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